Sycomore Asset Management Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sycomore Asset Management boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 51.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,318 shares of the medical research company’s stock after buying an additional 7,929 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.5% of Sycomore Asset Management’s holdings, making the stock its 20th biggest position. Sycomore Asset Management’s holdings in Thermo Fisher Scientific were worth $12,131,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in TMO. Legacy Investment Solutions LLC purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth $26,000. Peterson Financial Group Inc. purchased a new position in Thermo Fisher Scientific in the third quarter worth about $27,000. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $28,000. Missouri Trust & Investment Co purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TMO shares. Bank of America cut their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Barclays decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Finally, UBS Group increased their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $658.00.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now owns 111,192 shares in the company, valued at $58,960,669.92. The trade was a 8.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock worth $11,231,699 over the last 90 days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.2 %

TMO opened at $571.44 on Monday. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average of $547.34 and a 200 day moving average of $572.26. The firm has a market cap of $218.58 billion, a P/E ratio of 34.57, a P/E/G ratio of 3.18 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock repurchase program on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.